BioMarin Pharma (BMRN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec3

HSBC Increased Holdings in Bausch Health Companies

09:22

Nov21

Eagle Health Investments LP reduces holdings in Bausch Health Companies Inc.

09:49

Nov9

Campbell & CO Increases Holdings in BioMarin Pharmaceutical Inc.

09:34

Nov4

BioMarin Pharmaceuticals Receives FDA Priority Review for PALYNZIQ® Treatment Expansion

01:37

Nov2

Wall Street Zen downgrades BMRN's rating to hold from buy

05:12

Nov1

Morgan Stanley Maintains Buy Rating on BioMarin Pharmaceutical

03:52

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 776.13 M, Net Income -30.74 M, EPS -0.16

BioMarin Pharmaceutical Inc. (BMRN.US) Q3 2025 Earnings Conference Call

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 825.41 M, Net Income 240.53 M, EPS 1.2297

BioMarin Pharmaceutical Inc. (BMRN.US) Q2 2025 Earnings Conference Call

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 745.15 M, Net Income 185.69 M, EPS 0.9544

BioMarin Pharmaceutical Inc. (BMRN.US) Q1 2025 Earnings Conference Call

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change